Processa Pharmaceuticals, Inc. disclosed a material event
SEC 8-KRead source ↗
Processa Pharmaceuticals, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders9 buying, 0 selling45 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds7 adding, 3 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 12% in the quarter to 2025-09-30, the 3rd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Processa Pharmaceuticals, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 176% and a beta of 1.0 against the S&P 500.
Latest results
- Earnings per share
- -$1.75 against an average estimate of -$2.00: beat by 12.5%
- Share reaction
- +1.0% in the first session after the results on March 31, 2023, against +1.8% for the S&P 500
Price chart
- 1 day-2.1%
- 1 week+3.1%
- 1 month+14.9%
- This year-35.8%
- 1 year-81.0%
- 5 years-99.9%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- March 31, 2023
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Leadership
Processa Pharmaceuticals, Inc. announced a director or officer change; reported shareholder vote results
SEC 8-KRead source ↗ - Leadership
Processa Pharmaceuticals, Inc. entered a material agreement; ended a material agreement; completed an acquisition or disposal; sold unregistered shares; announced a director or officer change; amended its charter or bylaws; made a public disclosure
SEC 8-KRead source ↗
No model value for Processa Pharmaceuticals, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Processa Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10%: the 10-year Treasury yield (4.9%) plus a beta of 1.12 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Processa Pharmaceuticals, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Processa Pharmaceuticals, Inc.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Sept 2025 | −$2.00 | −$1.75 | +12.5% |
| Jun 2025 | −$5.75 | −$6.25 | −8.7% |
| Mar 2025 | −$19.25 | −$7.50 | +61.0% |
| Dec 2024 | −$23.00 | −$18.50 | +19.6% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 1.9% of tradable shares
- Days to cover
- 0.27 at average volume
- Short interest, 1 month
- +210% to October 15, 2026
- Held by institutions
- 19% of shares
- Held by insiders
- 15.0% of shares
- Employees
- 12 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| PCSA | −26% | −78% | −70% | −87% | −87% | −36% |
| Industry peers (median) | −18% | −49% | −13% | −2% | +9% | −12% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| PCSA | 33% | 25% | 25% | 25% | 33% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| PCSA | −69% | −79% | −86% | −88% | −88% | −64% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 3, 2015: 100% from October 19, 2017 to October 8, 2026. Getting back needed a 1324715% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $1.35 – $9.25
- From 52-week high
- −80.0%
- vs 50-day average
- +0.2%
- vs 200-day average
- −21.4%
- Volatility (1 year)
- 176%
- Beta vs S&P 500
- 1.01
Share price after results
- Next day
- 3 up, 3 down typical move ±2.8%
- After a week
- 3 up, 3 down typical move ±6.0%
- After a month
- 3 up, 3 down typical move ±22.3%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| March 31, 2023 | +1.0% | +1.8% | +4.2% | +39.6% |
| November 8, 2022 | −2.8% | −1.5% | −2.4% | −15.9% |
| August 12, 2022 | +3.7% | +2.1% | +2.4% | −15.4% |
| August 13, 2021 | −5.8% | +0.4% | −7.2% | +25.6% |
| May 13, 2021 | +0.6% | +2.8% | +10.5% | +9.8% |
| March 25, 2021 | −2.7% | +2.2% | −9.2% | −27.3% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $498,316
- Institutions reporting
- 12
- Shares held vs prior quarter
- ▲ 43.8%
- Positions opened / closed
- 4 / 2
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Connective Capital Management, LLC | $163,726 | 85K | 32.9% | ▲ 20.6% |
| Stonepine Capital Management, LLC | $105,600 | 55K | 21.2% | 0.0% |
| Geode Capital Management, LLC | $42,412 | 22K | 8.5% | ▼ 11.3% |
| Citadel Advisors LLC | $40,908 | 21K | 8.2% | New |
| Stonex Group Inc. | $29,623 | 11K | 5.9% | New |
| Xtx Topco Ltd | $25,521 | 13K | 5.1% | New |
| Jane Street Group, LLC | $25,466 | 13K | 5.1% | New |
| Vanguard Capital Management LLC | $24,440 | 13K | 4.9% | 0.0% |
| Vanguard Fiduciary Trust Co | $20,845 | 11K | 4.2% | 0.0% |
| UBS Group AG | $14,964 | 8K | 3.0% | ▲ 207.9% |
| Tower Research Capital LLC (TRC) | $4,798 | 2K | 1.0% | ▲ 172.2% |
| Jones Financial Companies LLLP | $13 | 0K | 0.0% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Processa Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $224,965 45 trades by 9 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $224,965 net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Ng George K Chief Executive Officer | July 1, 2026 | Buy | 3,057 | $1.93 | $5,900 |
| Young David Pres. Research & Development | June 30, 2026 | Buy | 2,531 | $1.93 | $4,885 |
| Skibsted Russell Chief Financial Officer | June 30, 2026 | Buy | 3,277 | $1.93 | $6,325 |
| Lin Patrick Chief Business - Strategy Off | June 30, 2026 | Buy | 2,106 | $1.93 | $4,065 |
| Guy Wendy Chief Administrative Officer | June 30, 2026 | Buy | 2,436 | $1.93 | $4,701 |
| Guy Wendy Chief Administrative Officer | June 15, 2026 | Buy | 2,118 | $2.22 | $4,702 |
| Lin Patrick Chief Business - Strategy Off | June 15, 2026 | Buy | 1,831 | $2.22 | $4,065 |
| Ng George K Chief Executive Officer | June 15, 2026 | Buy | 2,465 | $2.22 | $5,472 |
| Skibsted Russell Chief Financial Officer | June 15, 2026 | Buy | 2,654 | $2.22 | $5,892 |
| Young David Pres. Research & Development | June 15, 2026 | Buy | 2,067 | $2.22 | $4,589 |
| Guy Wendy Chief Administrative Officer | May 29, 2026 | Buy | 1,829 | $2.57 | $4,701 |
| Lin Patrick Chief Business - Strategy Off | May 29, 2026 | Buy | 1,582 | $2.57 | $4,066 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around July 3, 2023 estimated from the company's past filing pattern, not announced
- March 31, 2023
- November 8, 2022
- August 12, 2022
- August 13, 2021
- May 13, 2021
- March 25, 2021
Recent SEC filings
- 8-K Current report
- DEF 14A Proxy statement
- S-3 S-3
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Processa Pharmaceuticals, Inc. in brief
- What does Processa Pharmaceuticals, Inc. do?
- Processa Pharmaceuticals, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
- What is Processa Pharmaceuticals, Inc.'s stock ticker?
- Processa Pharmaceuticals, Inc. trades under the ticker PCSA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Processa Pharmaceuticals, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Connective Capital Management, LLC, Stonepine Capital Management, LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Processa Pharmaceuticals, Inc. stock?
- Over the last 12 months, Processa Pharmaceuticals, Inc.'s directors and officers reported 45 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
Follow research on Processa Pharmaceuticals, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.